Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

(2016) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC-MS/MS

(2016) Sandeep R. Kunati et al.   BIOMEDICAL CHROMATOGRAPHY

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

(2016) Emmanuel Seront et al.   BJU INTERNATIONAL

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

(2016) Maria I. Carlo et al.   ONCOLOGIST

A viral kinase mimics S6 kinase to enhance cell proliferation

(2016) Aadra Prashant Bhatt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

(2013) D. Roy et al.   CANCER RESEARCH

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics

(2012) Qingsong Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphatase and Tensin Homolog on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma

(2011) Debasmita Roy et al.   AMERICAN JOURNAL OF PATHOLOGY

Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks

(2011) Brian Magnuson et al.   BIOCHEMICAL JOURNAL

Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma

(2011) Susan E. Krown et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rapamycin Blocks Production of KSHV/HHV8: Insights into the Anti-Tumor Activity of an Immunosuppressant Drug

(2011) Lisa A. Nichols et al.   PLoS One

Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines

(2010) Antonino Carbone et al.   AIDS

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas

(2010) A. P. Bhatt et al.   BLOOD

Rapamycin inhibits mTORC1, but not completely

(2009) Carson C. Thoreen et al.   Autophagy

Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma

(2009) P Gasperini et al.   LEUKEMIA

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

(2008) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Activation of Akt through gp130 Receptor Signaling Is Required for Kaposi's Sarcoma-Associated Herpesvirus-Induced Lymphatic Reprogramming of Endothelial Cells

(2008) V. A. Morris et al.   JOURNAL OF VIROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA